Sight Sciences Inc Stock

$3.98

0.75% yesterday

Nasdaq, Nov 25, 10:00 pm CET

ISIN

US82657M1053

Symbol

SGHT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Sight Sciences Inc Stock price

$3.98

-29.52 88.12% 5Y

Nasdaq, Closing price Mon, Nov 25 2024

-0.03 0.75%

ISIN

US82657M1053

Symbol

SGHT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Key metrics

Market capitalization	$202.00m
Enterprise Value	$118.73m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	1.49
P/S ratio (TTM) P/S ratio	2.54
P/B ratio (TTM) P/B ratio	2.11
Revenue growth (TTM) Revenue growth	-3.99%
Revenue (TTM) Revenue	$79.54m
EBIT (operating result TTM) EBIT	$-49.71m
Free Cash Flow (TTM) Free Cash Flow	$-26.13m
Cash position	$118.56m
EPS (TTM) EPS	$-1.01
P/E forward	negative
P/S forward	2.48
EV/Sales forward	1.46
Short interest	3.05%

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Get Started for Free Today

Sight Sciences Inc Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Sight Sciences Inc forecast:

6x Hold

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Sight Sciences Inc forecast:

Buy

14%

Hold

86%

Analyst Estimates with Stock Price Targets

Financial data from Sight Sciences Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	80 80	4% 4% 100%
- Direct Costs	12 12	7% 7% 15%
Gross Profit	68 68	3% 3% 85%
- Selling and Administrative Expenses	100 100	12% 12% 125%
- Research and Development Expense	17 17	12% 12% 22%
EBITDA	-49 -49	21% 21% -62%
- Depreciation and Amortization	0.58 0.58	54% 54% 1%
EBIT (Operating Income) EBIT	-50 -50	21% 21% -63%
Net Profit	-50 -50	18% 18% -63%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Sight Sciences Inc Stock News

Neutral

GlobeNewsWire

●

7 days ago

Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference

MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it will present at the upcoming Piper Sandler 36th Annual Healthcare Conference, in New York, NY.

Neutral

Seeking Alpha

●

17 days ago

Sight Sciences, Inc. (SGHT) Q3 2024 Earnings Call Transcript

Sight Sciences, Inc. (NASDAQ:SGHT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul Badawi - Co-Founder & Chief Executive Officer Alison Bauerlein - Chief Financial Officer Matt Link - Chief Commercial Officer Conference Call Participants Macauley Kilbane - William Blair Phil Dantoin - Piper Sandler Nelson Cox - Lake...

Neutral

GlobeNewsWire

●

about one month ago

Sight Sciences to Report Third Quarter Financial Results on November 7, 2024

MENLO PARK, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the third quarter ended September 30, 2024, after the market close on ...

More Sight Sciences Inc News

Company Profile

Sight Sciences, Inc. is a medical device company, which engages in the provision of glaucoma implants for treatment of irreversible blindness. It also develops pharmaceuticals, drug delivery systems, and diagnostics for the treatment of ophthalmic conditions. The firms products include viscosurgical system and trabeculotomy instrument. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.

Head office	United States
CEO	Paul Badawi
Employees	214
Founded	2011
Website	www.sightsciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now